Search hospitals

>

Massachusetts

>

Boston

Brigham and Women's Hospital

Claim this profile

Boston, Massachusetts 02115

Global Leader in HIV Infection

Global Leader in Human Immunodeficiency Virus Infection

Conducts research for Heart Failure

Conducts research for Breast Cancer

Conducts research for Cancer

2238 reported clinical trials

222 medical researchers

Photo of Brigham and Women's Hospital in BostonPhoto of Brigham and Women's Hospital in Boston

Summary

Brigham and Women's Hospital is a medical facility located in Boston, Massachusetts. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Heart Failure, Breast Cancer, Cancer and other specialties. Brigham and Women's Hospital is involved with conducting 2,238 clinical trials across 1,946 conditions. There are 222 research doctors associated with this hospital, such as Geoffrey I. Shapiro, Glenn J. Hanna, MD, Omar Nadeem, MD, and Christina M Dieli-Conwright, PhD.

Area of expertise

1

HIV Infection

Global Leader

Brigham and Women's Hospital has run 101 trials for HIV Infection. Some of their research focus areas include:

HIV-1 positive
CD4⁺
CD8⁺
2

Human Immunodeficiency Virus Infection

Global Leader

Brigham and Women's Hospital has run 95 trials for Human Immunodeficiency Virus Infection. Some of their research focus areas include:

HIV-1 positive
CD4⁺
CD8⁺

Top PIs

Clinical Trials running at Brigham and Women's Hospital

Prostate Cancer

Bladder Cancer

Multiple Myeloma

Diabetes

Heart Failure

Brain Tumor

Small Cell Lung Cancer

Cancer

Insomnia

Atrial Fibrillation

Image of trial facility.

18F-DCFPyl PET Imaging

for Prostate Cancer

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

Recruiting

3 awards

Phase 4

8 criteria

Image of trial facility.

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Brigham and Women's Hospital?

Where is Brigham and Women's Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Brigham and Women's Hospital accept?

What awards or recognition has Brigham and Women's Hospital received?